Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
KEPIVANCE vs OXERVATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Kepivance (palifermin) is a recombinant human keratinocyte growth factor (KGF) that binds to the KGF receptor, a splice variant of fibroblast growth factor receptor 2 (FGFR2b), stimulating proliferation, differentiation, and migration of epithelial cells, including those in the gastrointestinal tract.
OXERVATE (becaplermin) is a recombinant human platelet-derived growth factor (rh PDGF-BB) that promotes wound healing by stimulating chemotaxis and mitogenesis of fibroblasts, smooth muscle cells, and other cells involved in tissue repair.
FDA-approved: To decrease the incidence and duration of severe oral mucositis in patients with hematologic malignancies receiving myelotoxic therapy requiring hematopoietic stem cell support.,Off-label: Prevention of oral mucositis in other cancers; management of acute radiation-induced mucositis.
Treatment of lower extremity diabetic neuropathic ulcers that extend into the subcutaneous tissue or beyond and have adequate blood supply,Off-label: Treatment of pressure ulcers, venous stasis ulcers
60 mcg/kg/day intravenously for 3 consecutive days before and 3 consecutive days after myelotoxic therapy.
1 drop in the affected eye(s) twice daily, approximately 6 hours apart.
Terminal elimination half-life is approximately 4.5 hours in healthy adults. In patients with renal impairment (Cr Cl <30 m L/min), half-life is prolonged up to 2-fold, requiring dose adjustment. The half-life supports once-daily dosing for 3 consecutive days before chemotherapy.
Terminal elimination half-life of Cenegermin is approximately 12 hours following topical ocular administration, supporting once-daily dosing
Metabolized via proteolytic degradation; no specific CYP450 involvement.
Becaplermin is a protein that is expected to be degraded into small peptides and amino acids via general protein catabolism; specific hepatic metabolism is not a significant pathway.
Primarily renal; approximately 90% of the dose is excreted unchanged in urine within 24 hours via glomerular filtration and tubular secretion. Minimal biliary/fecal elimination (<5%).
Primarily renal elimination of the active metabolite (Cenegermin) as small peptides and amino acids; unchanged drug excretion is negligible
Approximately 95% bound to plasma proteins, primarily albumin.
Cenegermin binding to plasma proteins is minimal (<10%) due to its small protein nature
Volume of distribution at steady state (Vd_ss) is approximately 0.2 L/kg, indicating limited extravascular distribution, consistent with a large protein-bound molecule. Does not distribute extensively into tissues.
Vd not determined for topical ocular route; systemic exposure is low, with Vd estimated less than 0.1 L/kg based on limited systemic absorption
Subcutaneous administration: Absolute bioavailability is approximately 90% compared to intravenous administration. Not available orally; only given subcutaneously.
Topical ocular: Systemic bioavailability is negligible (<1%) due to low corneal penetration and extensive proteolysis at the ocular surface
No dose adjustment is recommended for renal impairment, but monitor serum creatinine.
No dose adjustment required for renal impairment.
No specific dose adjustment for Child-Pugh class A or B; use caution in severe impairment.
No dose adjustment required for hepatic impairment.
Safety and efficacy not established; no recommended pediatric dose.
Safety and efficacy in pediatric patients have not been established.
No specific dose adjustment, but consider age-related renal and hepatic function decline.
No specific dose adjustment required; use same dosing as adults.
None.
OXERVATE has been associated with an increased risk of mortality from secondary malignancies in patients who have had a malignant neoplasm. The drug should not be used in patients with active malignancy.
Potential for stimulation of epithelial tumor growth (use caution in patients with non-hematologic malignancies).,Risk of allergic reactions including anaphylaxis.,May cause oral mucosal thickening and dental abnormalities.,Avoid use within 24 hours before or after myelotoxic chemotherapy.
Increased risk of malignancy in patients with a history of malignancy; application to ulcers with malignant cells may promote tumor growth; use only on clean, non-infected ulcers; monitor for signs of infection; avoid application to wounds with exposed bone, tendon, or joint capsule.
Hypersensitivity to palifermin or any excipients.,Concurrent use within 24 hours of myelotoxic chemotherapy.
Known hypersensitivity to becaplermin or any product component; active neoplasm at the application site; patients with a history of malignancy (relative contraindication based on black box warning).
No specific food interactions have been reported for KEPIVANCE. Maintain adequate nutrition and hydration as recommended by your healthcare provider.
None known; no significant food interactions reported.
KEPIVANCE (palifermin) is a recombinant human keratinocyte growth factor. No adequate and well-controlled studies in pregnant women. In animal reproduction studies, palifermin was not teratogenic in rats or rabbits at doses up to 100 mg/kg/day (IV), which produced exposures approximately 40 and 80 times the human exposure at the recommended clinical dose of 60 mcg/kg/day, based on AUC. However, there are no human data. Risk in first trimester: unknown; second and third trimesters: unknown.
OXERVATE contains cenegermin, a recombinant human nerve growth factor. No adequate and well-controlled studies in pregnant women. Animal reproductive studies have not been conducted. Risk cannot be ruled out; use only if potential benefit justifies potential risk to fetus. First trimester: unknown risk; second and third trimesters: unknown risk.
It is not known whether palifermin is excreted in human milk. No data on M/P ratio. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from palifermin, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
No data on presence in human milk, effects on breastfed infant, or milk production. Caution advised; M/P ratio unknown.
No pharmacokinetic data in pregnancy. No dose adjustment recommendations are provided for pregnancy; use only if clearly needed.
No pharmacokinetic studies in pregnancy; dose adjustments not established. Use standard dosing with caution.
KEPIVANCE (palifermin) is a recombinant human keratinocyte growth factor used to decrease the incidence and duration of severe oral mucositis in patients with hematologic malignancies undergoing myelotoxic therapy requiring hematopoietic stem cell support. Administer as a 3-day course of 60 mcg/kg/day IV bolus for 3 consecutive days before and 3 consecutive days after myelotoxic therapy. Must be given at least 24 hours before and after chemotherapy; do not administer within 24 hours of chemotherapy due to risk of enhanced cytotoxicity. Monitor for skin reactions, oral/perioral edema, and taste alteration. Contraindicated in patients with known hypersensitivity to E. coli-derived proteins.
OXERVATE (cenegermin-bkbj) is a recombinant human nerve growth factor for neurotrophic keratitis. Administer as one drop in the affected eye(s) six times daily at 2-hour intervals for 8 weeks. Refrigerate at 2-8°C; do not freeze. Protect from light. Discard unused drops after 1 week of first opening. Monitor for corneal epithelial defect closure. Use with caution in patients with active ocular infections or inflammation.
KEPIVANCE reduces the severity and duration of mouth sores caused by high-dose chemotherapy.,It is given as a short intravenous infusion once daily for 3 days before and 3 days after your chemotherapy.,You may experience swelling of the mouth, tongue, or lips; skin rash; or changes in taste. Report these to your healthcare team.,Do not receive KEPIVANCE within 24 hours before or after chemotherapy.,Inform your doctor if you have any allergies, especially to E. coli-derived products.
Wash hands before each use.,Instill one drop in the affected eye(s) every 2 hours, 6 times daily.,Refrigerate the medication at all times; do not freeze.,Use within 1 week after opening the vial.,Avoid touching the dropper tip to any surface.,Do not use contact lenses during treatment.,Report any eye pain, redness, or vision changes immediately.,Complete the full 8-week course even if symptoms improve.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about KEPIVANCE vs OXERVATE, answered by our medical review team.
KEPIVANCE is a Growth Factor that works by Kepivance (palifermin) is a recombinant human keratinocyte growth factor (KGF) that binds to the KGF receptor, a splice variant of fibroblast growth factor receptor 2 (FGFR2b), stimulating proliferation, differentiation, and migration of epithelial cells, including those in the gastrointestinal tract.. OXERVATE is a Growth Factor (Ophthalmic) that works by OXERVATE (becaplermin) is a recombinant human platelet-derived growth factor (rh PDGF-BB) that promotes wound healing by stimulating chemotaxis and mitogenesis of fibroblasts, smooth muscle cells, and other cells involved in tissue repair.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between KEPIVANCE and OXERVATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of KEPIVANCE is: 60 mcg/kg/day intravenously for 3 consecutive days before and 3 consecutive days after myelotoxic therapy.. The standard adult dose of OXERVATE is: 1 drop in the affected eye(s) twice daily, approximately 6 hours apart.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between KEPIVANCE and OXERVATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. KEPIVANCE is classified as Category C. KEPIVANCE (palifermin) is a recombinant human keratinocyte growth factor. No adequate and well-controlled studies in pregnant women. In animal reproduction studies, palifermin was . OXERVATE is classified as Category C. OXERVATE contains cenegermin, a recombinant human nerve growth factor. No adequate and well-controlled studies in pregnant women. Animal reproductive studies have not been conducte. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.